4basebio PLC Stock OTC Markets
Stocks
FBSB.F
GB00BMCLYF79
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 81.58M 110M 95.18M 88.89M 153M 10.47B 156M 1.04B 409M 5.25B 413M 404M 17.37B | P/E 2026 * |
-
| P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 81.88M 110M 95.53M 89.22M 154M 10.51B 156M 1.05B 410M 5.27B 414M 406M 17.43B | EV / Sales 2026 * |
29.2x | EV / Sales 2027 * | 8.94x |
| Free-Float |
38.75% | Yield 2026 * |
-
| Yield 2027 * | - |
| Manager | Title | Age | Since |
|---|---|---|---|
Amy Walker
CEO | Chief Executive Officer | 33 | 10/02/2026 |
Daniel Jones
CTO | Chief Tech/Sci/R&D Officer | - | 01/03/2025 |
Scott Lorimer
COO | Chief Operating Officer | - | 12/03/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Heikki Lanckriet
BRD | Director/Board Member | 48 | 22/12/2020 |
Amy Walker
BRD | Director/Board Member | 33 | 08/08/2024 |
| Chairman | 60 | 08/07/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 110M | |
| +0.99% | +1.78% | +4.07% | +16.73% | 49.47B | |
| +3.71% | +9.40% | +486.98% | +592.14% | 43.61B | |
| +5.60% | +10.21% | +16.76% | +85.72% | 39.6B | |
| +2.70% | +1.57% | +33.39% | +8.85% | 39.29B | |
| +2.21% | +6.75% | +21.31% | +53.37% | 32.43B | |
| +2.23% | +4.71% | - | - | 16.84B | |
| +0.97% | +2.35% | +37.75% | +126.84% | 16.49B | |
| -0.11% | +2.41% | +6.24% | +18.87% | 14.01B | |
| +0.75% | +15.04% | +78.59% | +30.30% | 12.77B | |
| Average | +1.90% | +6.32% | +85.64% | +116.60% | 29.39B | |
| Weighted average by Cap. | +2.54% | +6.10% | +104.25% | +140.79% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.8M 3.78M 3.27M 3.05M 5.27M 360M 5.34M 35.8M 14.04M 180M 14.17M 13.87M 596M | 12M 16.19M 14M 13.08M 22.57M 1.54B 22.91M 153M 60.15M 772M 60.73M 59.45M 2.55B |
| Net income | -17.1M -23.06M -19.95M -18.63M -32.16M -2.2B -32.64M -219M -85.72M -1.1B -86.54M -84.71M -3.64B | - |
| Net Debt | 300K 405K 350K 327K 564K 38.52M 573K 3.84M 1.5M 19.31M 1.52M 1.49M 63.87M | 25.7M 34.66M 29.99M 28.01M 48.34M 3.3B 49.06M 329M 129M 1.65B 130M 127M 5.47B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
